Devyser Diagnostics AB (ST:DVYSR) — Market Cap & Net Worth
Market Cap & Net Worth: Devyser Diagnostics AB (DVYSR)
Devyser Diagnostics AB (ST:DVYSR) has a market capitalization of $117.80 Million (Skr1.09 Billion) as of August 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #18529 globally and #322 in its home market, demonstrating a 4.82% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Devyser Diagnostics AB's stock price Skr65.20 by its total outstanding shares 16788555 (16.79 Million). See Devyser Diagnostics AB capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Devyser Diagnostics AB Market Cap History: 2021 to 2026
Devyser Diagnostics AB's market capitalization history from 2021 to 2026. Data shows change from $160.08 Million to $117.80 Million (-6.47% CAGR).
Index Memberships
Devyser Diagnostics AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.92 Billion | 0.74% | #30 of 281 |
Weight: Devyser Diagnostics AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Devyser Diagnostics AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Devyser Diagnostics AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.82x
Devyser Diagnostics AB's market cap is 0.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $160.08 Million | $93.48 Million | -$20.73 Million | 1.71x | N/A |
| 2022 | $130.08 Million | $126.61 Million | -$45.95 Million | 1.03x | N/A |
| 2023 | $142.01 Million | $169.30 Million | -$53.60 Million | 0.84x | N/A |
| 2024 | $214.10 Million | $216.90 Million | -$61.50 Million | 0.99x | N/A |
| 2025 | $206.33 Million | $250.50 Million | -$8.40 Million | 0.82x | N/A |
Competitor Companies of DVYSR by Market Capitalization
Companies near Devyser Diagnostics AB in the global market cap rankings as of August 4, 2026.
Key companies related to Devyser Diagnostics AB by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #113 globally with a market cap of $186.27 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #180 globally with a market cap of $130.57 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #239 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #113 | Abbott Laboratories | NYSE:ABT | $186.27 Billion | $107.12 |
| #180 | Stryker Corporation | NYSE:SYK | $130.57 Billion | $341.20 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #239 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $86.68 |
Devyser Diagnostics AB Historical Marketcap From 2021 to 2026
Between 2021 and today, Devyser Diagnostics AB's market cap moved from $160.08 Million to $ 117.80 Million, with a yearly change of -6.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr117.80 Million | -42.91% |
| 2025 | Skr206.33 Million | -3.63% |
| 2024 | Skr214.10 Million | +50.76% |
| 2023 | Skr142.01 Million | +9.17% |
| 2022 | Skr130.08 Million | -18.74% |
| 2021 | Skr160.08 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Devyser Diagnostics AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $117.80 Million USD |
| MoneyControl | $117.80 Million USD |
| MarketWatch | $117.80 Million USD |
| marketcap.company | $117.80 Million USD |
| Reuters | $117.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, … Read more